Predictors of failure with high-flow nasal cannula oxygen in COVID-19 patients
Predictores de fracaso con cánula nasal de alto flujo de oxígeno en pacientes COVID-19.
Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.
Show authors biography
Introduction: COVID-19 has generated challenges due to the high demand for health care services, making it necessary to seek ventilatory support alternatives that allow us to fulfill the needs of the population. It is important to have tools that allow to detect the failure of non-invasive ventilatory strategies early and to identify the need for intubation on time.
Objective: Identify the variables associated with failure of high-flow nasal cannula treatment (HFNC) on COVID-19 patients.
Materials and Methods: Analytical observational, cross-sectional study of 68 patients in the intensive care unit with COVID-19, who received treatment with HFNC. The variables of the study were evaluated at three time points, at 24, 48 and 72 hours. A bivariate and multivariate analysis was performed between those who failed and those who were successful.
Results: In the bivariate analysis, the variables that presented a statistically significant relationship at 24h were: No increase in work of breathing (WOB) (p=0.000), normal oxygen saturation (SatO2) (p=0.006). At 48h: No increase in WOB (p=0.014), normal SatO2 (p=0.005), mild to moderate partial pressure arterial oxygen/fraction inspired oxygen ratio (P/F ratio) (p=0.039). At 72h failed: severe P/F ratio (p=0.000), Increased WOB (p=0.001) and ROX index less than 4.88 (p=0.023). According to multivariate analysis the predictive variables for the therapeutic failure at 24h were: FIO2, SatO2, WOB; at 48h: FIO2 and SatO2.
Conclusions: Increased FIO2>70%, increased WOB and SpO2 less than 88% are variables associated with failure of HFNC, and facilitate clinical decisions on whether or not to progress with invasive ventilatory support.
Article visits 1664 | PDF visits 1068
Downloads
- Umakanthan S, Sahu P, Ranade A V., Bukelo MM, Rao JS, Abrahao-Machado LF, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020;96(1142):753-8. doi: 10.1136/postgradmedj-2020-138234
- Messika J, Ahmed K Ben, Gaudry S, Miguel-Montanes R, Rafat C, Sztrymf B, et al. Use of high-flow nasal cannula oxygen therapy in subjects with ARDS: A 1-year observational study. Respir Care. 2015;60(2):162–9. doi: 10.4187/respcare.03423
- Cinesi Gómez C, Peñuelas Rodríguez O , Luján Torné M L, Egea Santaolalla C, Masa Jiménez J F , García Fernández J, et al. Clinical consensus recommendations regarding non-invasive respiratory support in the adult patient with acute respiratory failure secondary to SARS-CoV-2 infection. Esp Anestesiol Reanim. 2020 Jan 67(5):261-270. doi: 10.1016/j.redar.2020.03.006
- García-Pereña L, Ramos Sesma V, Tornero Divieso ML, Et, al. Benefits of early use of high-flow-nasal-cannula (HFNC) in patients with COVID-19 associated pneumonia. Med Clin (Barc). 2021 Jun 16:S0025-7753(21)00322-5. doi: 10.1016/j.medcli.2021.05.015.
- Alshahrani MS, Alshaqaq HM, Alhumaid J, et al. High-Flow Nasal Cannula Treatment in Patients with COVID-19 Acute Hypoxemic Respiratory Failure: A Prospective Cohort Study. Saudi J Med Med Sci. 2021 Sep-Dec;9(3):215-222. doi: 10.4103/sjmms.sjmms_316_21.
- Johns Hopkins University (13 abril 2022). COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Disponible en: https://gisanddata.maps.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6
- Frat J-P, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure. N Engl J Med. 2015;372(23):2185-96. doi: 10.1056/NEJMoa1503326
- Xiaofeng Ou, Yusi Hua. Effect of high-flow nasal cannula oxygen therapy in adults with acute hypoxemic respiratory failure: a meta-analysis of randomized controlled trials. 2017;189(7):E 260-267. doi: 10.1503/cmaj.160570
- Wei-Jie Guan, Zheng-Yi Ni, Yu Hu, Wen-Hua Liang, Chun-Quan Ou , Jian-Xing He, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020;382(18):1708-20. doi: 10.1056/NEJMoa2002032
- Wang K, Zhao W, Li J, Shu W, Duan J. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China. Ann Intensive Care. 2020;10(1):1-5. doi:10.1186/s13613-020-00653-z
- A Belenguer-Muncharaz, H Hernández-Garcés. Indication of high-flow oxygen therapy in patients with SARS-CoV-2 pneumonia. Med Intensiva. 2020;1605(1):1-6. doi: 10.1016/j.medin.2020.11.001
- Roca O, Riera J, Torres F, Masclans JR. High-flow nasal oxygen therapy in acute respiratory failure. Respir Care. 2010 Apr;55(4):408-13. PMID: 20406507.
- Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. mayo 2020;46(5):854–887. Disponible en: http://link.springer.com/10.1007/s00134-020-06022-5 doi:10.1007/s00134-020-06022-5
- Byung Ju Kang, Younsuck Koh, Chae-Man Lim, Jin Won Huh, Seunghee Baek, Myongja Han, et al. Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. Intensive Care Med. 2015;41(4):623-32. doi: 10.1007/s00134-015-3693-5
- Artacho Ruiz R, Artacho Jurado B, Caballero Güeto F, Cano Yuste A, Durbán García I, García Delgado F, et al. Predictors of success of high-flow nasal cannula in the treatment of acute hypoxemic respiratory failure. Med Intensiva. 2021;45(2):80-7. doi: 10.1016/j.medin.2019.07.012
- Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernández G , et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med. 2019;199(11):1368-76. doi: 10.1164/rccm.201803-0589OC
- Ricard JD, Roca O, Lemiale V, Corley A, Braunlich J, Jones P, et al. Use of nasal high flow oxygen during acute respiratory failure. Intensive Care Med. 2020;46(12):2238-47. doi: 10.1007/s00134-020-06228-7
- Hu M, Zhou Q, Zheng R, Li X, Ling J, Chen Y, et al. Application of high-flow nasal cannula in hypoxemic patients with COVID-19: a retrospective cohort study. BMC Pulm Med. 2020;20(1):1–7. doi: 10.1186/s12890-020-01354-w
- Ding L, Wang L, Ma W, He H. Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: A multi-center prospective cohort study. Crit Care. 2020;24(1):1–8. doi: 10.1186/s13054-020-2738-5
- Duan J, Han X, Bai L, Zhou L, Huang S. Assessment of heart rate, acidosis, consciousness, oxygenation, and respiratory rate to predict noninvasive ventilation failure in hypoxemic patients. Intensive Care Med. 2017;43(2):192–9. doi: 10.1007/s00134-016-4601-3
- Palencia-Mojica CL, Valero-Ortiz AS, Silva-Rodríguez LJ. Comportamiento clínico y gasométrico en falla respiratoria aguda tratada con cánula nasal de alto flujo. Univ y Salud. 2020;22(2):102–11. doi: 10.22267/rus.202202.181.
- Parke RL, Eccleston ML, McGuinness SP. The effects of flow on airway pressure during nasal high-flow oxygen therapy. Respir Care. 2011;56(8):1151–5. doi: 10.4187/respcare.01106
- Mellado-Artigas R, Mujica LE, Ruiz ML, Ferreyro BL, Angriman F, Arruti E, et al. Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study. J Intensive Care. 2021;9(1):1–9. doi: 10.1186/s40560-021-00538-8
- Koga Y, Kaneda K, Fujii N, Tanaka R, Miyauchi T, Fujita M, et al. Comparison of high‐flow nasal cannula oxygen therapy and non‐invasive ventilation as first‐line therapy in respiratory failure: a multicenter retrospective study. Acute Med Surg. 2020;7(1):1–7. doi: 10.1002/ams2.461.